Nivolumab and ipilimumab are PD-1 and CTLA-4 inhibitors, respectively, that was recently granted accelerated FDA approval on 10 March 2020 for second-line therapy in advanced HCC previously treated with sorafenib. Here, CTLA4 is linked to hepatocellular carcinoma.